NewS Archive

From Good to Great: Unlocking a biopharma platform’s full potential

A Recipe For Start-Up Success With A Platform Technology

The Busiest Dealmakers Of 2022

Seattle biotech Bonum raises $93M Series A round

Good Therapeutics spinout Bonum banks $93 million in Series A

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

After $250M Roche buyout, a startup plans a second strike with fresh funding

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs